Three New Methods for Diagnosing Pancreas Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of Copenhagen.
Recruitment status was  Recruiting
Information provided by:
University of Copenhagen Identifier:
First received: November 25, 2005
Last updated: February 25, 2009
Last verified: February 2009
The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.

Condition Intervention
Pancreas Cancer
Procedure: Ultrasound and contrast agent

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer

Resource links provided by NLM:

Further study details as provided by University of Copenhagen:

Estimated Enrollment: 80
Study Start Date: February 2005
Estimated Study Completion Date: January 2009
Intervention Details:
    Procedure: Ultrasound and contrast agent
    contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspicion of cancer of the pancreas
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00259532

Contact: Hanne S Grossjohann, MD +45 35453419

Copenhagen University Hospital Recruiting
Copenhagen, Denmark, 2100
Contact: Hanne S Grossjohann, MD    +45 35453419   
Principal Investigator: Hanne S Grossjohann, MD         
Sponsors and Collaborators
University of Copenhagen
Principal Investigator: Michael B Nielsen, DMSc Department of Radiology, Section of Ultrasound
  More Information Identifier: NCT00259532     History of Changes
Other Study ID Numbers: (KF) 01 268342 
Study First Received: November 25, 2005
Last Updated: February 25, 2009
Health Authority: Denmark: Ethics Committee

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases processed this record on May 25, 2016